ACQUISITION

3 Months Ended

Mar. 31, 2013

ACQUISITION [Abstract]

ACQUISITION

NOTE 2—ACQUISITION

On June 25, 2012 (the "Acquisition Date"), pursuant to the terms of an Amended and Restated Agreement and Plan of Merger (the "Acquisition Agreement"), a wholly-owned subsidiary of the Company merged with and into eBioscience, Inc. ("eBioscience") with eBioscience surviving as a wholly-owned subsidiary of the Company (the "Acquisition"). eBioscience specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses.

The results of operations of the acquired eBioscience business and the fair values of the assets acquired and liabilities assumed have been included in the accompanying Consolidated Financial Statements since the Acquisition. For the three months ended March 31, 2013, the Company recorded $19.0 million in revenue and recognized a net loss of $3.9 million from eBioscience. No amounts were recognized from eBioscience during the three months ended March 31, 2012. The Company considered the eBioscience fair value analysis to be final as of December 31, 2012.